Nano mRNA Co., Ltd. logo

Nano mRNA Co., Ltd. (3NQ)

Market Open
12 Jun, 06:14
XDUS XDUS
0. 52
-0
-0.9434%
- Market Cap
- P/E Ratio
- Div Yield
0 Volume
- Eps
0.53
Previous Close
Add Transaction
Day Range
0.52 0.52
Year Range
0.51 1.29
Want to track 3NQ and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

3NQ trading today lower at €0.52, a decrease of -0.9434% from yesterday's close, completing a monthly decrease of -10.2564% or -€0.06. Over the past 12 months, 3NQ stock lost -29.5302%.
3NQ is not paying dividends to its shareholders.
The last earnings report, released on Aug 07, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Nano mRNA Co., Ltd. has completed 1 stock splits, with the recent split occurring on Mar 27, 2014.
The company's stock is traded on 4 different exchanges and in various currencies, with the primary listing on XFRA (EUR).

3NQ Chart

Nano mRNA Co., Ltd. (3NQ) FAQ

What is the stock price today?

The current price is €0.52.

On which exchange is it traded?

Nano mRNA Co., Ltd. is listed on XDUS.

What is its stock symbol?

The ticker symbol is 3NQ.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

Has Nano mRNA Co., Ltd. ever had a stock split?

Nano mRNA Co., Ltd. had 1 splits and the recent split was on Mar 27, 2014.

Nano mRNA Co., Ltd. Profile

Biotechnology Industry
Healthcare Sector
Dr. Shiro Akinaga Ph.D. CEO
XDUS Exchange
JP3651120002 ISIN
Japan Country
18 Employees
- Last Dividend
27 Mar 2014 Last Split
- IPO Date

Overview

NANO MRNA Co.,Ltd., based in Tokyo, Japan, is at the forefront of pharmaceutical research and development, embracing micellar nanoparticles technology to create breakthrough treatments. Founded in 1996 and originally known as NanoCarrier Co., Ltd., the company underwent a name change in June 2023 to better reflect its focus on mRNA-based therapies. NANO MRNA Co.,Ltd. is dedicated to addressing complex medical challenges, with a significant emphasis on tissue generation, vaccines, and cancer treatments, utilizing advanced biotechnological methods.

Products and Services

  • RUNX1 (mRNA) for Tissue Generation and Vaccines

    This pipeline product leverages mRNA technology to foster innovations in tissue regeneration and vaccine development, positioned to make significant impacts in medical treatments and preventive measures.

  • NC-6100 PRDM14 (siRNA) for Breast Cancer - Phase I Clinical Trials

    Engaging siRNA technology, this product is currently in phase I clinical trials, focusing on the treatment of breast cancer. It represents NANO MRNA’s commitment to combating one of the most common cancers affecting women worldwide.

  • TUG1 (ASO) for Glioblastoma Multiforme

    Targeting glioblastoma multiforme, a highly aggressive brain tumor, this antisense oligonucleotide (ASO) therapy is under development, showcasing the company's endeavors to tackle hard-to-treat cancers.

  • Complex, Antibacterial Ear Drops

    A commercially available product, Complex is an antibacterial ear drop solution designed to treat ear infections, demonstrating NANO MRNA's ability to address everyday health concerns alongside its more groundbreaking research efforts.

  • Cosmetic Raw Material

    Expanding its reach beyond pharmaceuticals, NANO MRNA Co.,Ltd. also supplies raw material for cosmetics, tapping into the extensive applications of nanotechnology for beauty and skincare solutions.

  • Platelet-Rich Therapy

    Another innovative service provided by NANO MRNA Co.,Ltd. involves platelet-rich therapy, a cutting-edge treatment designed to accelerate the healing of injured tendons, ligaments, muscles, and joints, showcasing the diverse applications of their research in enhancing human health and recovery.

Contact Information

Address: Atago Green Hills MORI Tower
Phone: 81 3 6432 4791